In tight next-gen pneu­mo­coc­cal vac­cine race with Pfiz­er, Mer­ck reads out topline pe­di­atric da­ta

The FDA is set to de­cide on Pfiz­er’s 20-va­lent pneu­mo­coc­cal con­ju­gate vac­cine for adults in June — a month be­fore Mer­ck’s PDU­FA date for its 15-va­lent can­di­date. But the Ke­nil­worth, NJ-based phar­ma isn’t go­ing down with­out a fight.

On Thurs­day, Mer­ck read out topline re­sults from two Phase III pe­di­atric stud­ies, and the com­pa­ny says it’s on track to sub­mit a sup­ple­men­tary BLA by the end of the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER